Evidence map›Paper›PMID 33381475›Full record

ReviewCanadian journal of gastroenterology & hepatology2020

Regulating Intestinal Microbiota in the Prevention and Treatment of Alcohol-Related Liver Disease.

Xin Chi, Calvin Q Pan, Shunai Liu, Danying Cheng, Ziwen Cao, Huichun Xing

Open access · goldAbstract readReview
In one paragraph

Review in Canadian journal of gastroenterology & hepatology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 2 pooled it
0.8field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 2 syntheses or guidelines pooled it, 13 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Investigation of the hemostatic mechanism ofAnnals of translational medicine · 2022
    Article
  5. Review
  6. Review
  7. Review
  8. Gut Microbiome and Alcohol-associated Liver Disease.Journal of clinical and experimental hepatology
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 2 countries.

Xin ChiCenter of Liver Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, China.ORCID 0000-0002-0301-5254
Calvin Q PanCenter of Liver Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, China.ORCID 0000-0002-3723-6688
Shunai LiuBeijing Key Laboratory of Emerging Infectious Diseases, Institute of Infectious Disease, Beijing Ditan Hospital, Capital Medical University, Beijing, China.ORCID 0000-0002-5688-8470
Danying ChengCenter of Liver Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, China.ORCID 0000-0001-6462-9244
Ziwen CaoDepartment of Immunology, Capital Medical University, Beijing, China.ORCID 0000-0002-4037-4264
Huichun XingCenter of Liver Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, China.ORCID 0000-0002-9111-9669
Capital Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

When alcohol-related liver disease occurs, the number and composition ratio of intestinal microorganisms will accordingly change. The alcohol-induced changes in the intestinal microbiota play a pivotal role in the process of developing the alcohol-related liver disease through the translocation of microbial products due to increased intestinal permeability. In recent years, therapeutic interventions with a concentration on regulating intestinal microbiota have been conducted for patients with alcohol-related liver disease. We aimed to provide a critical review and updates on the prevention and treatment of alcohol-related liver disease through regulating intestinal microbiota. A literature search was performed on the PubMed database for studies published in English about the therapeutic intervention with microbiota using animal models and patients with alcohol-related liver disease (1/2010-4/2020). The accumulating pieces of evidence suggest that the therapeutic use of probiotics, prebiotics, antibiotics, phages, or fecal microbial transplantation may have several influences on alcohol-related liver disease patients. Emergent data unveiled that these interventions can further regulate the composition of intestinal microbiota, minimize the negative impact of microbiota on the liver, and prevent disease progression from mild to severe alcoholic hepatitis, fibrosis, cirrhosis, or even liver cancer. The current review provides updates on the advances of therapeutic interventions with the effects of regulating intestinal microbiota on patients who have alcohol-related liver disease. In addition, the data gaps and research directions on further exploration of the role of intestinal microbiota for the management of the alcohol-related liver disease are also discussed.

Indexed as

Gastrointestinal MicrobiomeLiver Diseases, AlcoholicProbioticsAnimalsFecal Microbiota TransplantationHumansPrebioticsPrebiotics

Identifiers

PMID33381475
PMCPMC7759392
OpenAlexW3111741055

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.